RE:RE:RE:RE:RE:Nothing to be excited Also looks like 1 maybe 2 months of cash left. if the share price was higher probably would have warrants exercised to fill the coffers but isn't that the point of the financiers to shorti the stock forcing them to issue eve. more at a lower price. Until the company is cash flow positive they need financing and the financiers know that and will short the stock so they get more shares and more warrants. Than when the company is finally able to stand on its own without financing they will dump on it
I expect an announcement of financing any day and at a very low share price They have stage where they want them and they will keep shorting the stock so stage has no choice but to give out shares at ridiculously low prices Deal with the devil until bigger revenues come on or the shorters win
brad129 wrote:
I did read that as well, just seems like a bit of fluff to dull the pain of the financials, as I stated when it came out.
it would have definitely been nice to see a rise in revenue not a fall, they always claim slower numbers in fourth quater due to holidays. You don't really want more staff performing less tests. Anyone know what the capacity per day the lab could perform when it comes to Aristotle tests. Even if all lab revenue was Aristotle that would be under 5 tests per day on a 5 day work week.
molotov420 wrote: What they launched was a new program called COC Plus. From the PR:
COC Plus is a new physician led program centered on nutrition and other health interventions to help address a patient’s specific cancer and is designed to be used alongside standard of care.
I mean theyre not the worst financials I've ever seen, dont get me wrong...but no major leaps this quarter.